Katherine L.B. Borden, Ph.D.
- Principal Investigator, Structure and Function of the Cell Nucleus research unit, IRIC
- Professor, Department of Pathology and Cell Biology, Faculty of Medicine, Université de Montréal
Research topic and relevance
Katherine Borden and her team are trying to answer one of the fundamental questions in cancer biology: how do normal cells become transformed in cancer, particularly leukemia? Their research focuses on a particular protein, the eIF4E, and how its dysregulation leads to transformation and leukemia. A better understanding of the function and subsequent biochemical underpinnings of this protein could prove useful in the development of therapies to treat leukemia. One such therapy is ribavirin, which successfully targeted eIF4E in poor prognosis acute myeloid leukemia (AML) leading to remissions in some patients. Ongoing trials are focused on increasing the durability and frequency of remissions by combining ribavirin with other agents (www.ribatrial.com).